Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™
- 16 April 2015
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (8) , 2175-2184
Abstract
Calcium use was common and remained high among women on osteoporosis therapy. Use of calcium-supplemented pharmacologic therapy increased from 65.1 to 76.0 % in these women (mean follow-up, 27.5 months). Over 12 months, calcium discontinuation was fairly similar among women using calcium only (23.7 %) and women supplementing pharmacologic therapy with calcium (22.5 %). Calcium has an important role in bone health. This study describes calcium use and persistence in a postmenopausal osteoporosis treatment cohort. Subject-reported calcium use was analyzed for 3,722 participants of the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE USTM) who used calcium either as their sole osteoporosis treatment (calcium only) or to supplement pharmacologic osteoporosis therapy (supplementers). Descriptive analyses were conducted. Kaplan-Meier methods were used to estimate the probability of discontinuing calcium therapy, and logistic regression was used to assess associations (age-adjusted odds ratios) between healthy behaviors and calcium use. At entry, there were 711 calcium-only subjects and 1,960 of 3,011 subjects on pharmacologic osteoporosis therapy also supplementing with calcium (supplementers). The percentage of supplementers increased from 65.1 to 76.0 % during follow-up (mean, 27.5 months). During the first 12 months on study, the probability of calcium discontinuation was 23.7 % (95 % confidence interval [CI], 20.7 − 27.0) among calcium-only subjects and 22.5 % (95 % CI, 20.7–24.5) among supplementers. Supplementers who discontinued pharmacologic therapy were more likely to discontinue calcium than supplementers who continued pharmacologic therapy (34.9 versus 14.8 %). Overall 54.2 % of calcium-only subjects who discontinued calcium and 42.3 % of supplementers who discontinued calcium resumed calcium use during follow-up. Regular exercise was positively correlated with calcium use at study entry. Calcium supplementation in pharmacologically treated subjects increased over time. Persistence with calcium was high. Discontinuation of pharmacologic osteoporosis therapy was associated with an increased likelihood of discontinuing calcium use.Keywords
This publication has 32 references indexed in Scilit:
- Calcium Intake and Serum Concentration in Relation to Risk of Cardiovascular Death in NHANES IIIPLOS ONE, 2013
- Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort studyOsteoporosis International, 2012
- Calcium Intake and Risk of Cardiovascular DiseaseAmerican Journal of Cardiovascular Drugs, 2012
- Osteoporosis: now and the futureThe Lancet, 2011
- The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to KnowThe Journal of Clinical Endocrinology & Metabolism, 2011
- Estimation of Total Usual Calcium and Vitamin D Intakes in the United StatesThe Journal of Nutrition, 2010
- Vascular events in healthy older women receiving calcium supplementation: randomised controlled trialBMJ, 2008
- Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for OsteoporosisMayo Clinic Proceedings, 2007
- Calcium plus Vitamin D Supplementation and the Risk of FracturesNew England Journal of Medicine, 2006
- Importance of Calcium Co-Medication in Bisphosphonate Therapy of OsteoporosisDrugs & Aging, 2006